118 related articles for article (PubMed ID: 23234235)
21. Targeted chemotherapy of visceral leishmaniasis by lactoferrin-appended amphotericin B-loaded nanoreservoir: in vitro and in vivo studies.
Asthana S; Gupta PK; Jaiswal AK; Dube A; Chourasia MK
Nanomedicine (Lond); 2015; 10(7):1093-109. PubMed ID: 25929567
[TBL] [Abstract][Full Text] [Related]
22. Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis.
Abu Ammar A; Nasereddin A; Ereqat S; Dan-Goor M; Jaffe CL; Zussman E; Abdeen Z
Drug Deliv Transl Res; 2019 Feb; 9(1):76-84. PubMed ID: 30484256
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, characterization, and mechanistic studies of a gold nanoparticle-amphotericin B covalent conjugate with enhanced antileishmanial efficacy and reduced cytotoxicity.
Kumar P; Shivam P; Mandal S; Prasanna P; Kumar S; Prasad SR; Kumar A; Das P; Ali V; Singh SK; Mandal D
Int J Nanomedicine; 2019; 14():6073-6101. PubMed ID: 31686803
[TBL] [Abstract][Full Text] [Related]
24. Novel biodegradable poly(gamma-glutamic acid)-amphotericin B complexes show promise as improved amphotericin B formulations.
Dinh T; Zia Q; Zubair S; Stapleton P; Singh R; Owais M; Somavarapu S
Nanomedicine; 2017 Jul; 13(5):1773-1783. PubMed ID: 28216150
[TBL] [Abstract][Full Text] [Related]
25. Amphotericin B loaded nanoemulsion: Optimization, characterization and in-vitro activity against L. donovani promastigotes.
Prajapat VM; Aalhate M; Sriram A; Mahajan S; Maji I; Gupta U; Kumari D; Singh K; Kalia NP; Dua K; Singh SK; Singh PK
Parasitol Int; 2024 Jun; 100():102848. PubMed ID: 38159836
[TBL] [Abstract][Full Text] [Related]
26. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
27. Optimization of the hydrophobic domain in poly(ethylene oxide)-poly(varepsilon-caprolactone) based nano-carriers for the solubilization and delivery of Amphotericin B.
Falamarzian A; Lavasanifar A
Colloids Surf B Biointerfaces; 2010 Nov; 81(1):313-20. PubMed ID: 20674292
[TBL] [Abstract][Full Text] [Related]
28. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages.
Paila YD; Saha B; Chattopadhyay A
Biochem Biophys Res Commun; 2010 Aug; 399(3):429-33. PubMed ID: 20678487
[TBL] [Abstract][Full Text] [Related]
29. The effect of amphotericin b derivatives on Leishmania and immune functions.
Ehrenfreund-Kleinman T; Domb AJ; Jaffe CL; Nasereddin A; Leshem B; Golenser J
J Parasitol; 2005 Feb; 91(1):158-63. PubMed ID: 15856892
[TBL] [Abstract][Full Text] [Related]
30. Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis.
Shahnaz G; Edagwa BJ; McMillan J; Akhtar S; Raza A; Qureshi NA; Yasinzai M; Gendelman HE
Nanomedicine (Lond); 2017 Jan; 12(2):99-115. PubMed ID: 27879160
[TBL] [Abstract][Full Text] [Related]
31. In vitro synergistic effect of amphotericin B and allicin on Leishmania donovani and L. infantum.
Corral MJ; González-Sánchez E; Cuquerella M; Alunda JM
Antimicrob Agents Chemother; 2014; 58(3):1596-602. PubMed ID: 24366748
[TBL] [Abstract][Full Text] [Related]
32. Cholesterol improves stability of amphotericin B nanoemulsion: promising use in the treatment of cutaneous leishmaniasis.
Mansur-Alves I; Lima BLF; Santos TT; Araújo NF; Frézard F; Islam A; de Barros AL; Dos Santos DC; Fernandes C; Ferreira LA; Aguiar MM
Nanomedicine (Lond); 2022 Aug; 17(18):1237-1251. PubMed ID: 36189757
[No Abstract] [Full Text] [Related]
33. Investigations on feasibility of in situ development of amphotericin B liposomes for industrial applications.
Singodia D; Verma A; Khare P; Dube A; Mitra K; Mishra PR
J Liposome Res; 2012 Mar; 22(1):8-17. PubMed ID: 21682670
[TBL] [Abstract][Full Text] [Related]
34. Interaction between miltefosine and amphotericin B: consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro.
Ménez C; Buyse M; Besnard M; Farinotti R; Loiseau PM; Barratt G
Antimicrob Agents Chemother; 2006 Nov; 50(11):3793-800. PubMed ID: 16966395
[TBL] [Abstract][Full Text] [Related]
35. Effect of aggregation state on the toxicity of different amphotericin B preparations.
Espada R; Valdespina S; Alfonso C; Rivas G; Ballesteros MP; Torrado JJ
Int J Pharm; 2008 Sep; 361(1-2):64-9. PubMed ID: 18599228
[TBL] [Abstract][Full Text] [Related]
36. Development of dextrin-amphotericin B formulations for the treatment of Leishmaniasis.
Silva-Carvalho R; Fidalgo J; Melo KR; Queiroz MF; Leal S; Rocha HA; Cruz T; Parpot P; Tomás AM; Gama M
Int J Biol Macromol; 2020 Jun; 153():276-288. PubMed ID: 32145228
[TBL] [Abstract][Full Text] [Related]
37. Well-Tolerated Amphotericin B Derivatives That Effectively Treat Visceral Leishmaniasis.
Morelle C; Mukherjee A; Zhang J; Fani F; Khandelwal A; Gingras H; Trottier J; Barbier O; Leprohon P; Burke MD; Ouellette M
ACS Infect Dis; 2021 Aug; 7(8):2472-2482. PubMed ID: 34282886
[TBL] [Abstract][Full Text] [Related]
38. In vitro antileishmanial activity of amphotericin B loaded in poly(epsilon-caprolactone) nanospheres.
Espuelas MS; Legrand P; Loiseau PM; Bories C; Barratt G; Irache JM
J Drug Target; 2002 Dec; 10(8):593-9. PubMed ID: 12683663
[TBL] [Abstract][Full Text] [Related]
39. A novel formulation of solubilised amphotericin B designed for ophthalmic use.
Serrano DR; Ruiz-Saldaña HK; Molero G; Ballesteros MP; Torrado JJ
Int J Pharm; 2012 Nov; 437(1-2):80-2. PubMed ID: 22890190
[TBL] [Abstract][Full Text] [Related]
40. In vitro reversion of amphotericin B resistance in Leishmania donovani by poloxamer 188.
Espuelas S; Legrand P; Loiseau PM; Bories C; Barratt G; Irache JM
Antimicrob Agents Chemother; 2000 Aug; 44(8):2190-2. PubMed ID: 10898700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
